Kerstin Maria Kampa-Schittenhelm

Author

Also Known As

K M Kampa-Schittenhelm, K.M. Kampa-Schittenhelm, KERSTIN M. KAMPA-SCHITTENHELM, Kerstin Kampa, Kerstin Kampa-Schittenhelm, Kerstin Kampa‐Schittenhelm, Kerstin M Kampa, Kerstin M Kampa-Schittenhelm, Kerstin M. Kampa, Kerstin M. Kampa-Schittenhelm

Publications

622

Citations

H-Index

Concepts

All Affiliations

University of Tübingen University Children's Hospital Tübingen Oregon Health & Science University OHSU Knight Cancer Institute University Hospital Ulm

About

Kerstin Maria Kampa-Schittenhelm is an author at University of Tübingen specializing in medicine, tumor microenvironment, and apoptosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	197
2	Cell Biology	2	2	109
3	Immunology	2	2	141
4	Health Sciences	1	1	53
5	Pharmacology	1	1	88

Kerstin Maria Kampa-Schittenhelm

Publications

554

Citations

H-Index

Page 1

	Year	Citations
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms Kerstin Maria Kampa-Schittenhelm, Michael C. Heinrich, Figen Akmut, Molecular Cancer	2013	121
The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro Matthias Krusch, Julia Salih, Manuela Schlicke, The Journal of Immunology Cancer ImmunosurveillanceMedicineImmunologyTumor ImmunityNk Cells	2009	88
N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence Zhiping Wang, Yuangang Liu, Maho Takahashi, Proceedings of the National Academy of Sciences ApoptosisCell DeathCancer BiologyTumor BiologySignaling Pathway	2012	56
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia Kerstin Maria Kampa-Schittenhelm, Michael C. Heinrich, Figen Akmut, Molecular Cancer	2013	56
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage–response thresholds Kerstin Maria Kampa-Schittenhelm, Jared D. Acoba, Dexi Chen, Proceedings of the National Academy of Sciences Aspp2 AlleleApoptosisImmunologyCell DeathCell Proliferation	2009	53
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin Marcus M. Schittenhelm, Kerstin Maria Kampa-Schittenhelm, Kevin Yee, Cell Cycle	2009	35
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns Kerstin Maria Kampa-Schittenhelm, Olaf Salitzky, Figen Akmut, BMC Cancer	2016	33
Control of ASPP2/53BP2L Protein Levels by Proteasomal Degradation Modulates p53 Apoptotic Function Zhiyi Zhu, Jason Ramos, Kerstin Maria Kampa-Schittenhelm, Journal of Biological Chemistry	2005	32
Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure Marcus M. Schittenhelm, Barbara Illing, Figen Ahmut, PLoS ONE	2013	20
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant <i>KIT</i> D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia Kerstin Maria Kampa-Schittenhelm, Julia Frey, L A Haeusser, Oncotarget	2017	20

Page 1